Michael S Ingber, Ibrahim A Ibrahim, Kim A Killinger, Ananias C Diokno, Kenneth M Peters
{"title":"神经调节和女性性功能:难治性排尿症状的治疗是否有额外的益处?","authors":"Michael S Ingber, Ibrahim A Ibrahim, Kim A Killinger, Ananias C Diokno, Kenneth M Peters","doi":"10.1007/s00192-009-0900-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction and hypothesis: </strong>Women undergoing InterStim implantation for overactive bladder (OAB) or painful bladder syndrome (PBS) were prospectively evaluated to determine if neuromodulation has any effect on female sexual function (FSF).</p><p><strong>Methods: </strong>Sexually active women in our InterStim database completed a female sexual function index (FSFI) preoperatively and at 6 months.</p><p><strong>Results: </strong>Of 105 women, 54 have 6-month follow-up data. Of these, 27 were sexually active preoperatively and at follow-up. The mean (standard deviation (SD)) FSFI improved from 18.7 (6.8) preoperatively to 21.0 (6.0) postoperatively; however, this was not statistically significant (p = 0.220). Subgroup analysis of patients with OAB revealed that mean (SD) FSFI preoperatively was 18.6 (8.0) and 22.4 (6.4) at 6 months (p = 0.257). In the PBS group, mean (SD) FSFI was 18.8 (6.3) preoperatively and 18.7 (5.8) at 6 months (p = 0.98).</p><p><strong>Conclusions: </strong>Neuromodulation does not significantly improve FSF in a heterogenous population. Additional studies are needed to confirm the findings in our study.</p>","PeriodicalId":73495,"journal":{"name":"International urogynecology journal and pelvic floor dysfunction","volume":"20 9","pages":"1055-9"},"PeriodicalIF":0.0000,"publicationDate":"2009-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s00192-009-0900-3","citationCount":"17","resultStr":"{\"title\":\"Neuromodulation and female sexual function: does treatment for refractory voiding symptoms have an added benefit?\",\"authors\":\"Michael S Ingber, Ibrahim A Ibrahim, Kim A Killinger, Ananias C Diokno, Kenneth M Peters\",\"doi\":\"10.1007/s00192-009-0900-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction and hypothesis: </strong>Women undergoing InterStim implantation for overactive bladder (OAB) or painful bladder syndrome (PBS) were prospectively evaluated to determine if neuromodulation has any effect on female sexual function (FSF).</p><p><strong>Methods: </strong>Sexually active women in our InterStim database completed a female sexual function index (FSFI) preoperatively and at 6 months.</p><p><strong>Results: </strong>Of 105 women, 54 have 6-month follow-up data. Of these, 27 were sexually active preoperatively and at follow-up. The mean (standard deviation (SD)) FSFI improved from 18.7 (6.8) preoperatively to 21.0 (6.0) postoperatively; however, this was not statistically significant (p = 0.220). Subgroup analysis of patients with OAB revealed that mean (SD) FSFI preoperatively was 18.6 (8.0) and 22.4 (6.4) at 6 months (p = 0.257). In the PBS group, mean (SD) FSFI was 18.8 (6.3) preoperatively and 18.7 (5.8) at 6 months (p = 0.98).</p><p><strong>Conclusions: </strong>Neuromodulation does not significantly improve FSF in a heterogenous population. Additional studies are needed to confirm the findings in our study.</p>\",\"PeriodicalId\":73495,\"journal\":{\"name\":\"International urogynecology journal and pelvic floor dysfunction\",\"volume\":\"20 9\",\"pages\":\"1055-9\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/s00192-009-0900-3\",\"citationCount\":\"17\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International urogynecology journal and pelvic floor dysfunction\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s00192-009-0900-3\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2009/5/14 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International urogynecology journal and pelvic floor dysfunction","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00192-009-0900-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2009/5/14 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Neuromodulation and female sexual function: does treatment for refractory voiding symptoms have an added benefit?
Introduction and hypothesis: Women undergoing InterStim implantation for overactive bladder (OAB) or painful bladder syndrome (PBS) were prospectively evaluated to determine if neuromodulation has any effect on female sexual function (FSF).
Methods: Sexually active women in our InterStim database completed a female sexual function index (FSFI) preoperatively and at 6 months.
Results: Of 105 women, 54 have 6-month follow-up data. Of these, 27 were sexually active preoperatively and at follow-up. The mean (standard deviation (SD)) FSFI improved from 18.7 (6.8) preoperatively to 21.0 (6.0) postoperatively; however, this was not statistically significant (p = 0.220). Subgroup analysis of patients with OAB revealed that mean (SD) FSFI preoperatively was 18.6 (8.0) and 22.4 (6.4) at 6 months (p = 0.257). In the PBS group, mean (SD) FSFI was 18.8 (6.3) preoperatively and 18.7 (5.8) at 6 months (p = 0.98).
Conclusions: Neuromodulation does not significantly improve FSF in a heterogenous population. Additional studies are needed to confirm the findings in our study.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
